Pulse Biosciences, Inc. (PLSE)
NASDAQ: PLSE · Real-Time Price · USD
17.87
-0.44 (-2.40%)
Mar 3, 2025, 4:00 PM EST - Market closed
Company Description
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company.
The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.
The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015.
Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.
Pulse Biosciences, Inc.
| Country | United States |
| Founded | 2014 |
| IPO Date | May 18, 2016 |
| Industry | Medical Instruments & Supplies |
| Sector | Healthcare |
| Employees | 56 |
| CEO | Paul LaViolette |
Contact Details
Address: 3957 Point Eden Way Hayward, California 94545 United States | |
| Phone | 510 906 4600 |
| Website | pulsebiosciences.com |
Stock Details
| Ticker Symbol | PLSE |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001625101 |
| CUSIP Number | 74587B101 |
| ISIN Number | US74587B1017 |
| Employer ID | 46-5696597 |
| SIC Code | 3841 |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 27, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Feb 27, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Feb 4, 2025 | 8-K | Current Report |
| Jan 23, 2025 | 8-K | Current Report |
| Jan 14, 2025 | 8-K | Current Report |
| Jan 13, 2025 | 8-K | Current Report |
| Dec 26, 2024 | 8-K | Current Report |
| Dec 19, 2024 | SCHEDULE 13D/A | Filing |
| Dec 6, 2024 | 8-K | Current Report |
| Nov 26, 2024 | 8-K | Current Report |